Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 1
Please note: We are reviewing Western blot images included in the antibody testing data in our catalog, including those provided by third parties. Unless expressly labeled or annotated as “raw-unedited”, Western blot images included in the antibody testing data in our catalog may have been edited, optimized or otherwise adjusted for presentation.
Fenfluramine is a synthetic amphetamine derivative primarily known for its appetite suppressant properties, but it has been repurposed for use in treating epilepsy, particularly Dravet syndrome. The compound is characterized by its trifluoromethyl group, which has been substituted by the pentafluorosulfanyl group in analogs to enhance selectivity and efficacy as inhibitors of 5-hydroxytryptamine receptors. Fenfluramine's mechanism involves modulation of serotonin pathways, contributing to its therapeutic effects and potential adverse cardiovascular impacts. The NAV1.1 voltage-gated sodium channel gene is implicated in its anticonvulsant activity, highlighting the drug's multifaceted role in neuropharmacology. Fenfluramine's biosimilar development focuses on optimizing its molecular structure for improved safety and efficacy in clinical applications.
仅用于科研。不用于诊断过程。未经明确授权不得转售。